USE OF H3K9me3 MODULATION FOR ENHANCING COGNITIVE FUNCTION

Patent metadata

Field	Value
Publication number	US-2018228808-A1
Application number	US-201615580419-A
Country	US
Kind code	A1
Filing date	Jun 3, 2016
Priority date	Jun 8, 2015
Publication date	Aug 16, 2018
Grant date	—

Abstract

Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.

First claim

What is claimed is:

1 . A method of reversing cognition loss in an animal subject in need thereof, the method comprising:
selecting an animal subject with cognitive loss; and administering a therapeutically effective amount of a SUV39H1 inhibitor compound to said animal subject, wherein said therapeutically effective amount comprises single dosing for acute treatment and repeated dosing for chronic treatment.

2 . A method of reversing cognition loss in a patient in need thereof, the method comprising:
selecting a patient with loss of memory function; and administering to the patient a therapeutically effective amount of a SUV39H1 inhibitor compound together with a pharmaceutical cognitive enhancer, wherein said therapeutically effective amount comprises single dosing for acute treatment and repeated dosing for chronic treatment.

3 . The method of claim 2 , wherein the cognitive enhancer is a cholinesterase inhibitor.

4 . The method of claim 3 , wherein the cholinesterase inhibitor is selected from a group comprising tacrine, donepezil, rivastigmine, and galantamine.

5 . The method of claim 2 , wherein the cognitive enhancer is an NMDA antagonist or an NMDA agonist.

6 . The method of claim 2 , wherein the cognitive enhancer is an ampakine.

7 . The method of claim 2 , wherein the cognitive enhancer is a BZD/GABA receptor complex modulator.

8 . The method of claim 2 , wherein the cognitive enhancer is a serotonin antagonist.

9 . The method of claim 2 , wherein the cognitive enhancer is a nicotinic class compound.

10 . The method of claim 2 , wherein the cognitive enhancer is a muscarinic class compound.

11 . The method of claim 2 , wherein the cognitive enhancer is a PDE inhibitor.

12 . The method of claim 2 , wherein the cognitive enhancer is a G protein class compound.

13 . The method of claim 2 , wherein the cognitive enhancer is a channel modulator.

14 . The method of claim 2 , wherein the cognitive enhancer is an immunotherapeutic class compound.

15 . The method of claim 2 , wherein the cognitive enhancer is an anti-amyloid or amyloid lowering agent.

16 . The method of claim 2 , wherein the cognitive enhancer is a statin or a PPARS modulator.

17 . A method of enhancing cognition in a subject in need thereof, the method comprising:
selecting a subject in need of memory enhancement; and administering to the subject a therapeutically effective amount of a SUV39H1 inhibitor compound together with a lifestyle cognitive enhancer.

18 . The method of claim 17 , wherein the cognitive enhancer is physical exercise.

19 . The method of claim 17 , wherein the cognitive enhancer is mental exercise.

20 . The method of claim 17 , wherein the cognitive enhancer is dietary supplement.

21 . The method of claim 20 , wherein the supplement is an antioxidant.

22 . The method of claim 20 , wherein the supplement is a mitochondrial function enhancer.

23 . The method of claim 20 , wherein the supplement is caffeine.

24 . The method of claim 20 , wherein the supplement is omega-3.

25 . The method of claim 20 , wherein the supplement is Docosahexaenoic acid (DHA).

26 . A method of treatment, prevention or alleviation of a cognitive dysfunction of a living animal subject, including a human, the method comprising:
selecting a living animal subject with signs of cognitive loss; and administering to such living animal subject a therapeutically effective amount of a SUV39H1 inhibitor compound.

27 . A method of treatment and alleviation of anxiety related disorders in an animal subject in need thereof, the method comprising:
selecting an animal subject with anxiety related disorder; and administering a therapeutically effective amount of a SUV39H1 inhibitor compound to said animal subject, wherein said therapeutically effective amount comprises single dosing for acute treatment and repeated dosing for chronic treatment.

Assignees

• Univ California

Inventors

• Cotman Carl W
• Overman Larry E
• Snigdha Shikha

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K31/445

  Non condensed piperidines, e.g. piperocaine · CPC title

• A61K31/473

  ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/27

  of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine · CPC title